Skip to content
AnalystLens

Corteva, Inc. 8-K Report, Financial Results (May 7, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 7, 2025
Period End
May 7, 2025
Security
CTVA
In the record · 2019–202610-K710-Q238-K85

CTVA filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 85 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’21Feb ’21
  2. Restructuring8-K · Aug ’22Aug ’22
  3. Impairment8-K · Nov ’23Nov ’23
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.

Corteva (CTVA) reported first-quarter 2025 results that beat on profitability while sales dipped modestly.

Net sales were $4.42 billiona, down 2% year over year, but organic sales rose 3% as price (+1%) and volume (+2%) gains offset a 5% currency drag. GAAP EPS from continuing operations rose to $0.97 from $0.53, and Operating EBITDA climbed 15% to $1.19 billion. Operating EPS increased 27% to $1.13, driven by segment improvements: Seed Operating EBITDA rose 13% to $842 million with margin up about 390 basis points, and Crop Protection Operating EBITDA rose 22% to $377 million with margin up about 425 basis points.

Management attributed the margin expansion to net cost reductions, productivity, and raw material benefits. Management reaffirmed full-year 2025 guidance: net sales of $17.2 to $17.6 billionb, Operating EBITDA of $3.6 to $3.8 billion, and Operating EPS of $2.70 to $2.95 per share, implying roughly 10% growth at the midpoint for EBITDA and EPS. The company still plans about $1 billion in share repurchases in 2025.

Management expects high-single-digit volume gains in Crop Protection offset by low-single-digit price headwinds, and says tariffs are not expected to have a material net impact at current policies. Restructuring charges of $150 to $165 millionc are expected in 2025. Investors should note several watch items.

Reported figures in this filing are not GAAP-to-guidance reconciled for forward-looking non-GAAP measures. Balance sheet metrics show accounts receivable rising sharply to $8.29 billiond from $5.68 billion at year-end, while cash fell to $2.0 billion and short-term borrowings rose to $2.29 billion, reflecting the seasonal working capital build typical of the first quarter.

Operating cash flow from continuing operations was negative $2.1 billion, which is seasonal but worth monitoring. Latin America was the weakest region, with Seed sales down 32% due to reduced Argentina corn area.

02—Key points

Key Highlights

  1. Net sales of $4.42B, down 2% YoY; organic sales up 3% with price +1% and volume +2%, against a 5% currency headwind.
  2. GAAP EPS from continuing operations rose to $0.97 from $0.53; diluted EPS including discontinued operations was $0.95.
  3. Operating EBITDA up 15% to $1.19B; Operating EPS up 27% to $1.13 per share.
  4. Seed Operating EBITDA up 13% to $842M with margin improvement of about 390 bps; Crop Protection Operating EBITDA up 22% to $377M with margin improvement of about 425 bps.
  5. 2025 guidance reaffirmed: net sales $17.2-17.6B, Operating EBITDA $3.6-3.8B, Operating EPS $2.70-2.95, with about $1B in planned share buybacks.
  6. Latin America weakness: Seed sales down 32% on reduced Argentina corn area; EMEA Seed sales down 10% on timing shifts.
  7. Operating cash flow from continuing operations was -$2.1B, with receivables up to $8.3B from $5.7B at year-end, reflecting seasonal working capital build.

03—Questions

Frequently Asked Questions

  1. Did Corteva's first-quarter 2025 results show real earnings growth despite falling sales?

    Yes. Net sales fell 2% to $4.42B mainly because of currency, but organic sales rose 3%. Profitability improved more sharply: GAAP EPS from continuing operations nearly doubled to $0.97, and Operating EBITDA rose 15% to $1.19B. The gains came from cost reductions, productivity, raw material benefits, and better price realization in Seed.

  2. Is Corteva still on track to meet its 2025 guidance?

    Management reaffirmed full-year 2025 guidance, including net sales of $17.2-17.6B, Operating EBITDA of $3.6-3.8B, and Operating EPS of $2.70-2.95. The guidance implies about 10% growth at the midpoint for EBITDA and EPS. Q1 results were strong, but the company flagged a fluid macro environment, so the outlook depends on the remainder of the year.

  3. What are the main risks to Corteva's outlook highlighted in the filing?

    Key risks include crop price and margin moderation, shifts in planted area, trade uncertainty, and competitive pricing pressure in Crop Protection, where price declined 2%. Latin America is exposed to reduced Argentina corn area, and EMEA is affected by timing shifts. Management says tariffs are not expected to have a material net impact at current policies, but the risk is not eliminated.

  4. Why did operating cash flow turn significantly negative in the quarter?

    Operating cash flow from continuing operations was -$2.1B, driven by a seasonal build in accounts receivable ($2.5B increase) and deferred revenue declines, typical of Corteva's first-quarter pattern. Receivables reached $8.3B versus $5.7B at year-end, and short-term borrowings rose to $2.3B. Investors should watch whether collections normalize as the season progresses.

  5. How much is Corteva returning to shareholders in 2025?

    Corteva repurchased $270M of common stock in Q1 2025 and plans to buy back about $1 billion of shares during 2025. Dividends paid in the quarter totaled $116M. Diluted shares outstanding dropped to 686.6 million from 702.8 million a year earlier, which supports per-share earnings growth.

04—Continue

← View all 8-K filings